A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

NCT06869226 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

283

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Camrelizumab + Nab-paclitaxel + Cisplatin

Sponsor

Peking University Cancer Hospital & Institute